Vanguard Group Inc. Buys 94,885 Shares of The Chemours Company (NYSE:CC)

Vanguard Group Inc. boosted its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 0.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 15,223,961 shares of the specialty chemicals company's stock after buying an additional 94,885 shares during the period. Vanguard Group Inc. owned approximately 10.19% of Chemours worth $257,285,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Corient Private Wealth LLC boosted its position in shares of Chemours by 4.7% during the fourth quarter. Corient Private Wealth LLC now owns 13,428 shares of the specialty chemicals company's stock worth $227,000 after buying an additional 604 shares during the period. GAMMA Investing LLC lifted its stake in Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after acquiring an additional 765 shares in the last quarter. HUB Investment Partners LLC boosted its position in Chemours by 1.4% during the 4th quarter. HUB Investment Partners LLC now owns 58,250 shares of the specialty chemicals company's stock worth $984,000 after acquiring an additional 821 shares during the last quarter. ARGA Investment Management LP grew its stake in shares of Chemours by 0.7% during the 4th quarter. ARGA Investment Management LP now owns 148,614 shares of the specialty chemicals company's stock worth $2,512,000 after acquiring an additional 1,032 shares in the last quarter. Finally, Heritage Investors Management Corp raised its holdings in shares of Chemours by 1.1% in the fourth quarter. Heritage Investors Management Corp now owns 105,322 shares of the specialty chemicals company's stock valued at $1,780,000 after purchasing an additional 1,174 shares during the last quarter. Institutional investors own 76.26% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

CC has been the subject of a number of analyst reports. Barclays decreased their target price on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 1st. Morgan Stanley decreased their price objective on Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. BMO Capital Markets dropped their target price on Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a report on Wednesday, February 19th. Truist Financial began coverage on Chemours in a research note on Tuesday, January 28th. They issued a "buy" rating and a $27.00 price target for the company. Finally, Mizuho upgraded Chemours from a "neutral" rating to an "outperform" rating and set a $19.00 price objective on the stock in a research note on Thursday, March 27th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $22.56.

Chemours Stock Performance

Shares of CC traded up $2.31 during mid-day trading on Wednesday, reaching $11.89. The company's stock had a trading volume of 3,982,911 shares, compared to its average volume of 1,803,111. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70. The stock has a market cap of $1.78 billion, a P/E ratio of 20.86 and a beta of 1.84. The Chemours Company has a 1-year low of $9.34 and a 1-year high of $29.21. The business has a 50-day simple moving average of $14.83 and a two-hundred day simple moving average of $17.74.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. The firm had revenue of $1.36 billion during the quarter, compared to analysts' expectations of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. As a group, equities research analysts anticipate that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were issued a $0.25 dividend. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 annualized dividend and a yield of 8.41%. Chemours's dividend payout ratio is currently 175.44%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.